Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 3-(2-methoxyphenoxy)-n-methyl-3-phenylpropylamine
2. 3-(o-methoxyphenoxy)-n-methyl-3-phenylpropylamine
3. Dl-n-methyl-3-(o-methoxyphenoxy)-n-methyl-3-phenylpropylamine
4. Lilly 135252
5. Lilly 94939
6. Ly 135252
7. Ly 94939
8. Ly-135252
9. N-methyl-gamma-(2-methylphenoxy)phenylpropanolamine
10. Nisoxetine Hydrochloride
11. Nisoxetine Hydrochloride, (+-)-isomer
12. Nisoxetine, (+-)-isomer
1. 53179-07-0
2. 3-(2-methoxyphenoxy)-n-methyl-3-phenylpropan-1-amine
3. Compound 89218
4. 3-(2-methoxyphenoxy)-n-methyl-3-phenylpropylamine
5. 57226-61-6
6. Dl-n-methyl-3-(o-methoxyphenoxy)-n-methyl-3-phenylpropylamine
7. Nsc-283481
8. 3-(o-methoxyphenoxy)-n-methyl-3-phenylpropylamine
9. N-methyl-gamma-(2-methylphenoxy)phenylpropanolamine
10. Chembl295467
11. Chebi:73410
12. 17nv064b2d
13. Benzenepropanamine, Gamma-(2-methoxyphenoxy)-n-methyl-
14. Compound 89218; Nsc 283481
15. Ncgc00015715-04
16. Nisoxetine Inhibitor
17. Dsstox_cid_25175
18. Dsstox_rid_80724
19. Dsstox_gsid_45175
20. Nisoxetina
21. Nisoxetinum
22. Nisoxetine [usan:inn]
23. Cas-53179-07-0
24. Ly-94939
25. Unii-17nv064b2d
26. Nsc 283481
27. Ly 94939
28. Nisoxetine [inn]
29. Antioxidant1425
30. Nisoxetine (usan/inn)
31. Prestwick0_000910
32. Prestwick1_000910
33. Prestwick2_000910
34. Prestwick3_000910
35. Nisoxetine [usan]
36. Lopac0_000901
37. Bspbio_000760
38. Compound-89218
39. Schembl124289
40. Spbio_002959
41. Bpbio1_000836
42. Gtpl4637
43. Dtxsid0045175
44. Bdbm22417
45. Hms2089k13
46. Tox21 110203
47. Tox21_110203
48. Nsc283481
49. Pdsp1_000507
50. Pdsp2_000505
51. Tox21_110203_1
52. Ccg-204983
53. Db09186
54. Sdccgsbi-0050876.p002
55. Ncgc00015715-03
56. Ncgc00015715-05
57. Ncgc00015715-06
58. Ncgc00015715-08
59. Ncgc00015715-15
60. Ncgc00024945-02
61. Ncgc00024945-03
62. As-16468
63. Ab00514644
64. D05173
65. Ab00514644-07
66. N-methyl 3(o-methoxyphenoxy)-3-phenylpropylamine
67. N-methyl 3-(o-methoxyphenoxy)-3-phenylpropylamine
68. Q906885
69. [3-(2-methoxyphenoxy)-3-phenylpropyl](methyl)amine
70. N-methyl-3-phenyl-3-(o-methoxyphenoxy)-propylamine
71. Brd-a95696066-003-03-9
72. Brd-a95696066-003-06-2
73. (+/-)-3-(o-methoxyphenoxy)-n-methyl-3-phenylpropylamine
74. Benzenepropanamine, .gamma.-(2-methoxyphenoxy)-n-methyl-, (+/-)-
| Molecular Weight | 271.35 g/mol |
|---|---|
| Molecular Formula | C17H21NO2 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 7 |
| Exact Mass | 271.157228913 g/mol |
| Monoisotopic Mass | 271.157228913 g/mol |
| Topological Polar Surface Area | 30.5 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 253 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
38
PharmaCompass offers a list of Nisoxetine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nisoxetine manufacturer or Nisoxetine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nisoxetine manufacturer or Nisoxetine supplier.
PharmaCompass also assists you with knowing the Nisoxetine API Price utilized in the formulation of products. Nisoxetine API Price is not always fixed or binding as the Nisoxetine Price is obtained through a variety of data sources. The Nisoxetine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nisoxetine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nisoxetine, including repackagers and relabelers. The FDA regulates Nisoxetine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nisoxetine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Nisoxetine supplier is an individual or a company that provides Nisoxetine active pharmaceutical ingredient (API) or Nisoxetine finished formulations upon request. The Nisoxetine suppliers may include Nisoxetine API manufacturers, exporters, distributors and traders.
Nisoxetine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nisoxetine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nisoxetine GMP manufacturer or Nisoxetine GMP API supplier for your needs.
A Nisoxetine CoA (Certificate of Analysis) is a formal document that attests to Nisoxetine's compliance with Nisoxetine specifications and serves as a tool for batch-level quality control.
Nisoxetine CoA mostly includes findings from lab analyses of a specific batch. For each Nisoxetine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nisoxetine may be tested according to a variety of international standards, such as European Pharmacopoeia (Nisoxetine EP), Nisoxetine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nisoxetine USP).
